CRL · Earnings call · 2026Q2T · Full report

Competition and Pricing Pressure

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 17 · Surprise 24 · In source text

Charles River is monitoring the increasing capabilities of Chinese CROs, particularly their potential expansion from early-stage chemistry and biology into regulated work. Management said regulated work remains a minority of Chinese CRO activity and that global biopharma clients’ China investments are generally concentrated in early-stage R&D rather than regulated safety assessment. The company is differentiating its Western offering through service quality, speed, scale and supply-chain reliability, while viewing NHP availability as a competitive advantage. Pricing in the second quarter remained stable with no material change in discounting, but management expects pricing to improve as industry capacity fills, with any benefit likely to reach revenue in 2027 because of proposal-to-booking and backlog conversion lags.

Key facts

• The company believes pricing has not materially improved yet and remains stable at levels seen for the last few years; any pricing uptick would likely flow through in 2027 after backlog timing.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reports that pricing from some Chinese CROs doing work for the West is not too far off Western pricing anymore, but is still lower and will continue to be lower.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. states pricing for Chinese biotech and pharma is still considerably lower than Western pricing.

Impact estimates